Meet the ACF Scientific Advisory Council
Animal Cancer Foundation is pleased to welcome our new Scientific Advisory Council. Members, recognized experts in the fields of medical & veterinary oncology, collaborate on the creation of up-to-date Request for Proposals materials, including evaluative criteria, and advise the ACF Executive Board on the grant process, assuring that the foundation is supporting the most innovative comparative oncology research. David C. Levine, MD, ACF President, and Gerald S. Post, DVM, DACVIM (Oncology), ACF Vice-President, serve as co-chairs of the council.
DVM, MS, DACVIM (Oncology)
Dir of Clinical Studies, Medical Oncologist
Hope Veterinary Specialists
Craig A. Clifford, DVM, Diplomate ACVIM (Oncology), serves as Director of Clinical Studies, Hope Veterinary Specialists, Malvern, PA. Previously, he was Director of Clinical Research at Red Bank Veterinary Hospital.
Dr. Clifford received his DVM from Mississippi State University in 1999 and subsequently completed his internship in small animal medicine & surgery and his residency in oncology at the University of Pennsylvania. He has been a fellowship examiner for the Australian College of Veterinary Scientist, a member of the ACVIM residency training and credentials committee, a member of the Veterinary Cancer Society Executive Board & Founder of the VCS Residency Review Session at the annual meeting, a consultant to the Veterinary Information Network, Animal Clinical Investigations Network, Novartis Animal Health, Pfizer, Oasmia Pharmaceuticals, Boehringer Ingelheim, Pet Medicus Laboratories, and AB Science.
A Co-Founder of the Northeastern Veterinary Co-operative Oncology Group, Dr. Clifford is the author and/or co-author of multiple publications including: --D.M. Vail, H. von Euler, A.W. Rusk, L. Barber, CA. Clifford, et al. A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs. JVIM 2012 In Press.--CA Clifford, LP de Lorimier: Kirk's Current Veterinary Therapy XIV: Canine Hemangiosarcoma: Current Concepts, 2008.--CA Clifford, K Skorupski: The Histiocytic Diseases: In Withrow and MacEwen's "Small Animal Clinical Oncology". 2007.--KA Skorupski, CA Clifford, MC Paoloni, et al. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med 2007;21:121-6.--Heller DA, Clifford CA, Goldschmidt MH, et al. Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor. Vet Pathol 2005;42:350-3.--CA Clifford, ES Pretorius, C Weisse, et al. Magnetic resonance imaging of focal splenic and hepatic lesions in the dog. J Vet Intern Med. 2004;18:330-8.
American Cancer Society, President
Professor of Medicine
Professor of Epidemiology and Public Health
Yale University School of Medicine, New Haven, CT.
Vincent T. Devita, Jr., MD, Professor of Medicine, and Professor of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT., served as the Director of Yale Cancer Center from 1993 to July 2003. Dr. DeVita was appointed the Amy and Joseph Perella Professor of Medicine on 6 February 2004. Following Dr. DeVita’s tenure, the chair will be renamed the Vincent T. DeVita Professor of Medicine.
Dr. DeVita spent the early part of his career at the National Cancer Institute (NCI) of the National Institutes of Health. In 1980 he was appointed by the President of the United States as Director of NCI and the National Cancer Program. While at the NCI Dr. DeVita also served as Professor of Medicine at George Washington School of Medicine. In 1988 Dr. DeVita joined Memorial Sloan-Kettering Cancer Center as Physician-In-Chief, and incumbent of the Benno C. Schmidt Chair of Clinical Oncology. He served as Professor of Medicine at Cornell University School of Medicine until he returned to Yale in 1993.
Dr. DeVita has earned international recognition for his accomplishments. While at NCI, he was instrumental in developing combination chemotherapy programs that ultimately led to an effective regimen of curative chemotherapy of Hodgkin’s disease and diffuse large cell lymphomas. Along with colleagues at NCI, he developed the four-drug combination, known by the acronym MOPP, which increased the cure-rate for patients with advanced Hodgkin’s disease from nearly zero to over 70 percent. Dr. DeVita and his colleagues played a major role in the development of similar treatments for other lymphomas and cancers of the ovary and breast.
Dr. Devita serves on the editorial boards of numerous scientific journals and is the author or co-author of more than 450 scientific articles. He is one of the three editors of Cancer: Principles and Practice of Oncology, a comprehensive textbook in the field of cancer medicine; Biologic Therapy of Cancer, Progress in Oncology, and a textbook on AIDS, as well as The Cancer Journal: The Journal of Principles & Practice in Oncology. He also serves on the Editorial Board of Nature Reviews Clinical Oncology and is Editor-in-Chief of Current Clinical Trials: Oncology.
In 1972, Dr. DeVita received the Albert and Mary Lasker Medical Research Award for his contribution to the cure of Hodgkin’s disease. In 1980, he was awarded the Griffuel Prize by the Association for the Development of Research on Cancer, again for his important contributions to cancer chemotherapy, particularly his development of curative multiple drug therapy for Hodgkin’s disease and diffuse large-cell lymphoma. In 1985, Dr. DeVita was elected to the Institute of Medicine of the National Academy of Sciences and was presented the Perluigi Nervi Award for Cancer Research in Italy, the Medal of Honor from the American Cancer Society, and the Barbara Bohen Pfeiffer Aware from the Italian-American Foundation for Cancer Research. Awards for 1986 include the Tenth Richard and Hinda Rosenthal Award (American Association for Cancer Research, Inc.) and the Stanley G. Kay Memorial Award (D.C. American Cancer Society). In 1988, Dr. DeVita received the first Alessio Pezcoller Award from the European School of Oncology in Milan, Italy and The Surgeon General’s Exemplary Service Medal. In 1990, he was awarded the Armand Hammer Cancer Prize. In 1995, he was named a City of Medicine Awards winner for his work in cancer clinical research. The Commendatore of the Italian Republic order of merit was bestowed by the President of Italy in 1998. Dr. DeVita received two awards in 1999; the Mary Waterman Award from the Breast Cancer Alliance and the 50th Anniversary Commemorative Award from the Leukemia Society of America. He was the recipient of the Saul Rosenberg Research Award from the Lymphoma Research Foundation of America in 2000. In the year 2002, Dr. DeVita was elected to the European Academy of Sciences for his outstanding and lasting contribution to cancer research and medical education. Dr. DeVita received the 2007 ASCO Statesman Award and also the 2007 FREDDIE Award, a Public Service Award from the International Health & Medical Media Awards. In 2009 he received the Distinguished Medical Science Award from the Friends of the National Library of Medicine, Washington, D.C. and was also awarded the Honoris Causa in Medicine Degree from the National University of Athens, Greece.
Dr. DeVita was appointed by Senator Dianne Feinstein in 2000 to chair the National Cancer Legislative Advisory Committee (NCLAC), a Senate advisory committee working hand-in-hand with the National Dialogue on Cancer (NDC) spearheaded by former President George H.W. Bush, which made recommendations for revising and modernizing the National Cancer Act of 1971.
Born in Bronx, New York, March 7, 1935, to Isabelle LoNano and Vincent DeVita, both born in the United States, Dr. DeVita earned his Bachelor of Science degree from the College of William and Mary in 1957. He was awarded his M.D. degree with distinction from the George Washington University School of Medicine in 1961.
DVM, MS, Diplomate ACVIM (Oncology)
Diplomate ACVR (Radiation Oncology)
The Veterinary Cancer Center,
Dr. Farrelly received his DVM from Cornell University College of Veterinary Medicine in 1998 and subsequently completed an internship in small animal medicine and surgery at the Animal Medical Center in New York City followed by a residency in Medical Oncology. He then went on to complete a residency in Radiation Oncology at Cornell University in 2004 and from 2001 to 2004 was an Instructor in the Department of Molecular Medicine at the College of Veterinary Medicine. Following his residency Dr. Farrelly was the Director of Radiation Oncology at the Animal Medical Center from 2004 until 2012. During that time he received a Masters in Biostatistics from New York Medical College’s School of Health Sciences and Practice. In 2012 he joined the Veterinary Cancer Center where he practices both medical and radiation oncology. In 2006 Dr. Farrelly Received the Animal Medical Center Employee’s Award for Veterinarian of the Year. He has published articles on various types of cancer and has also acted as a statistician on numerous manuscripts.
Dr. med. vet. habil., BS, MS. PhD, Diplomate ACVP
Professor of Pathobiology and Diagnostic Investigation
Section Chief Anatomic Pathology
Michigan State University
College of Veterinary Medicine
East Lansing, MI
Dr. med. vet. habil. Matti Kiupel, BS, MS, PhD, DACVP, Fachtierarzt für Veterinär Pathologie, is a Professor in the Department of Pathobiology and Diagnostic Investigation at Michigan State University in the College of Veterinary Medicine and serves as the Section Chief of Anatomic Pathology in the Diagnostic center for Population and Animal Health. He is also the head of the histology and immunohistochemistry laboratory, one of the largest veterinary diagnostic molecular pathology laboratories in the country.
Dr. Kiupel received his veterinary degree from the Freie University of Berlin, Germany in 1996. While studying veterinary medicine he finished his bachelor degree in biology at the Humboldt-University, Berlin, Germany and completed his doctoral thesis research on canine malignant lymphomas in a collaborative study between the University of Cambridge, UK, the university of Utrecht, Netherlands and the Freie University, Berlin, Germany and was awarded the doctoral degree in 1999. Dr. Kiupel completed a residency in anatomic pathology from 1996 until 1999 and finished a PhD on the pathogenesis on porcine circovirus in 2001 at Purdue University, Indiana, USA. He has held a professorship in anatomic pathology since 2001 at Michigan State University and became section chief in 2006 and was promoted to full professor in 2012.
Dr. Kiupel has received many honors and awards including a merit scholarship from the Friedrich-Ebert-Foundation, Germany, a merit scholarship of the British Chamber of Commerce in Germany, the Charles Osborne Award from Purdue University, the Don Kahn Award in Virology of the American College of Veterinary Microbiologists, the Heinrich-Luessen-Award and the Ernst-Reuter-Award, both from the Freie University, Berlin, Germany, multiple Samuel W. Thompson Distinguished Lecturer Awards, the Barbara Jean Thompson Service Award, the Research Achievement Award of the American Ferret Association and he is a honorary member of the US Army Veterinary Corps.
Dr Kiupel has published close to 200 peer-reviewed scientific manuscripts and numerous book chapters in the field of veterinary and comparative pathology and specifically tumorpathology and was the lead author on the WHO fascicle of neuroendocrine tumors of domestic animals. He has been an invited speaker on topics of tumorpathology and diagnostic molecular pathology, in particular immunohistochemistry, worldwide. Dr. Kiupel is also the Associate Editor for Oncology in Veterinary Pathology and recently served as the guest editor of an issue dedicated to veterinary tumorpathology. Dr. Kiupel is chair of the ACVP oncology committee and past chair of the AAVLD pathology committee, he is a board member of the Charles Louis Davis, DVM Foundation and until recently served on the boards of directors for the Michigan Veterinary Medical Association. His laboratory has been selected for pathology and immunohistochemistry support of the Comparative Oncology Trials Consortium (COTC). He is currently working as Editor of the online World Small Animal Veterinary Association (WSAVA) classification of neoplastic diseases of animals and member of the National Cancer Institute (NCI) Comparative Melanoma Board.
DVM, PhD, Diplomate ACVIM (Oncology)
Associate Professor, The Thekla R. and Donald B. Shackelford
Professorship in Canine Medicine
The Ohio State University
College of Veterinary Medicine
Cheryl London, DVM, PhD, is an associate professor in Ohio State’s College of Veterinary Medicine, Department of Veterinary Biosciences, She holds the Thekla R. and Donald B. Shackelford Professorship in Canine Medicine and is Director of the Clinical Trials Office at the College of Veterinary Medicine. Her research interests include the use of spontaneous tumors in dogs and cats as models for human cancer, and the application of targeted therapies. Before coming to Ohio State in 2005, she was an assistant professor in the Department of Surgical and Radiological Sciences at the University of California Davis. Dr. London earned her DVM at Tufts University, completed her Residency in Medical Oncology at the University of Wisconsin-Madison, and her PhD at Harvard University, where she also completed a postdoctoral fellowship in the Department of Pathology.
VMD, Diplomate ACVIM (Oncology)
Associate Professor and Barbara Cox Anthony Chair in Oncology
Director of Clinical Research
Colorado State University Animal Cancer Center
College of Veterinary Medicine and Biomedical Sciences
Fort Collins, CO
Douglas H. Thamm, VMD, Diplomate ACVIM (Oncology), Associate Professor and Barbara Cox Anthony Chair in Oncology, serves as Director of Clinical Research at the Colorado State University Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences.
Dr. Thamm received his VMD from the University of Pennsylvania in 1995 and subsequently completed an internship in small animal medicine/surgery at the Red Bank Veterinary Referral Service in Red Bank, NJ. He completed his residency in oncology and a post-doctoral fellowship at the University of Wisconsin, School of Veterinary Medicine in Madison, Wisconsin. He became a consultant in Oncology at the University of Queensland School of Veterinary Science, Brisbane, Australia from 2001-2002. Returning to the United States, Dr. Thamm re-joined the University of Wisconsin, School of Veterinary Medicine as an assistant scientist for two years and then joined the Colorado State University Animal Cancer Center as an Assistant Professor in 2004. He is currently a member of the Colorado State University Cell and Molecular Biology Graduate Program and the University of Colorado Comprehensive Cancer Center. He is Co-Editor-In-Chief of the journal Veterinary and Comparative Oncology, and serves on advisory boards for several veterinary and human pharmaceutical companies.
In 2000, Dr. Thamm received the Travel Award, AACR Molecular Biology in Clinical Oncology Workshop. He was also awarded the E. Gregory MacEwen Young Investigator Award from the Veterinary Cancer Society in 2004 and the Pfizer Research Award from Colorado State University in 2007. He has authored or co-authored over 80 peer-reviewed publications, 20 book chapters, and 100 abstracts in the field of veterinary oncology and cancer research. His specific areas of research interest include,tyrosine kinase signaling in animal cancer cells, validation of biomarkers for novel therapeutics, and targeted therapy to enhance chemosensitivity
DVM, Diplomate ACVIM (Oncology)
Professor of Oncology, Barbara A. Suran Chair in Comparative Oncology
University of Wisconsin-Madison
Member of the UW Carbone Comprehensive Cancer Center
Director of the Center for Clinical Trials and Research at the School of
David M. Vail, DVM, Diplomate ACVIM (Oncology), Professor of Oncology, University of Wisconsin, Madison, WI. is a member of the UW Carbone Comprehensive Cancer Center and serves as Director of the Center for Clinical Trials and Research at the School of Veterinary Medicine.
Dr. Vail received his DVM from the University of Saskatchewan in 1984 and subsequently completed an internship in small animal medicine and surgery at Colorado State University prior to practicing in his native western Canada for two years. He completed a residency in Medical Oncology at the Animal Cancer Center, Colorado State University in 1990. He has held professorships in oncology at both the University of Wisconsin (1991-2004) and Colorado State University (2004-2006), before returning to Wisconsin in 2006.
Dr. Vail has received many honors and awards including, Connaught Labs Immunology Award, University of Saskatchewan Undergraduate Scholarship for Academic Achievement (1982, 1983), the J. Gordon Anderson Award in Clinical Medicine, The Calgary Academy Award in Clinical Medicine, the Upjohn Company (TUCO) Award, the Virgil and Mitzy Young Award in Post Graduate Medicine, The Mark Morris Sr. Distinguished Research Award, American Association of Feline Practitioners Research Award, The Hunting Retriever Club of America –Annual Research Award, and the 2011 Pfizer Award for Veterinary Research Excellence.
He has published over 120 peer-reviewed scientific manuscripts and 50 book chapters in the field of veterinary and comparative oncology and is co-editor of the textbook Small Animal Clinical Oncology. He is past Journal Editor for Veterinary and Comparative Oncology, President-Elect of the Veterinary Cancer Society, past President of the Canine Comparative Oncology and Genomics Consortium (CCOGC), and a founding member of the Comparative Oncology Trials Consortium (COTC). He is the past Chairman of the Scientific Advisory Boards of both the Morris Animal Foundation and the American College of Veterinary Internal Medicine Foundation.
Clinician scientist Immunology Program
Medical Oncologist (Melanoma)
Director of Immunotherapy Clinical Trials, Memorial Sloan- Kettering Cancer Center
Director of the Cancer Vaccine Collaborative (CVC).
Jedd Wolchok received his undergraduate degree from Princeton University and both M.D and Ph.D. from New York University, where he also fulfilled his residency program. He completed his fellowship at MSKCC and remained on faculty with an appointment in the Melanoma/Sarcoma Service.
Dr. Wolchok is currently Associate Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) with an expertise in the treatment of metastatic melanoma. His additional appointments include: Head of the Swim Across America Laboratory, one of the foremost immunotherapy and melanoma research groups in the country; Associate Director of the Ludwig Center for Cancer Immunotherapy (LCCI); Director of Immunotherapy Clinical Trials; and most recently, he has been appointed the Associate Chair of Medicine and leads the Immunotherapeutics Clinical Core. Dr. Wolchok has therefore helped establish MSKCC as a leader in the discovery and treatment of cancers with novel immunotherapies. With an active collaboration with Dr. James Allison, Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma. He also leads the MSKCC Immune Monitoring Facility, a world-renowned full-time core dedicated to the pre-clinical and clinical cellular, serological and pathological monitoring of clinical trials of new immunotherapeutic approaches. Currently, he is Principal Investigator of numerous ongoing clinical trials at MSKCC in the area of immunotherapy.
In 2011, Dr. Wolchok was named Director of the Cancer Vaccine Collaborative (CVC), a joint initiative between the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research (LICR). The CVC is an international academic clinical trials network dedicated to developing safe and effective therapeutic vaccines and other immunotherapies for cancer. The CVC has conducted nearly 50 early-phase clinical trials of different therapeutic cancer vaccines involving more than 950 patients with melanoma, lung, ovarian, prostate, breast, and other cancers.
Over the past 10 years, Dr. Wolchok has been an active mentor of medical and graduate students and postdoctoral fellows, and is the Director of the Summer Medical Student Program and co-Director of the Medical Oncology-Hematology Fellowship Program at MSKCC.
Dr. Wolchok’s awards include; Damon Runyon-Lilly Clinical Investigator Award, Julia Zelmanovich Young Alumni Award by New York University School of Medicine; Humanitarian Awards granted by the Melanoma Research Foundation and the Live, Love, Laugh Foundation and the Doctor of the Year by the Melanoma International Foundation. He has been a member of both AACR and ASCO since 1997 and 1998, respectively and the SU2C Melanoma Dream Team. Dr. Wolchok is a nationally and internationally recognized guest speaker of the field immunotherapy.